169 related articles for article (PubMed ID: 10377942)
1. Efficacy of antineoplastons A10 and AS2-1.
Burzynski SR
Mayo Clin Proc; 1999 Jun; 74(6):641-2. PubMed ID: 10377942
[No Abstract] [Full Text] [Related]
2. Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma.
Burzynski SR; Janicki TJ; Weaver RA; Burzynski B
Integr Cancer Ther; 2006 Mar; 5(1):40-7. PubMed ID: 16484713
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1.
Burzynski SR; Weaver RA; Janicki T; Szymkowski B; Jurida G; Khan M; Dolgopolov V
Integr Cancer Ther; 2005 Jun; 4(2):168-77. PubMed ID: 15911929
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma.
Buckner JC; Malkin MG; Reed E; Cascino TL; Reid JM; Ames MM; Tong WP; Lim S; Figg WD
Mayo Clin Proc; 1999 Feb; 74(2):137-45. PubMed ID: 10069350
[TBL] [Abstract][Full Text] [Related]
5. Complete response and long-term survival (>20 years) of a child with tectal glioma: a case report.
Burzynski SR; Burzynski GS; Janicki TJ; Marszalek A
Pediatr Neurosurg; 2015; 50(2):99-103. PubMed ID: 25926271
[TBL] [Abstract][Full Text] [Related]
6. Main editor's comment to the paper: the response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma. Stanislaw R. Burzynski, Tomasz J. Janicki, Gregory S. Burzynski, Ania Marszalek.
Di Rocco C
Childs Nerv Syst; 2014 Dec; 30(12):2063. PubMed ID: 25096071
[No Abstract] [Full Text] [Related]
7. Commentary: The response and survival of children with recurrent diffuse intrisic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma, by Burzynski G, et al.
Massimino M; Clerici CA
Childs Nerv Syst; 2014 Dec; 30(12):2065-6. PubMed ID: 25079885
[No Abstract] [Full Text] [Related]
8. Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report.
Burzynski SR; Weaver RA; Lewy RI; Janicki TJ; Jurida GF; Szymkowski BG; Khan MI; Bestak M
Drugs R D; 2004; 5(6):315-26. PubMed ID: 15563234
[TBL] [Abstract][Full Text] [Related]
9. Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients.
Tsuda H; Hara H; Eriguchi N; Nishida H; Yoshida H; Kumabe T; Sugita Y
Kurume Med J; 1995; 42(4):241-9. PubMed ID: 8667595
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report.
Burzynski SR; Lewy RI; Weaver RA; Axler ML; Janicki TJ; Jurida GF; Paszkowiak JK; Szymkowski BG; Khan MI; Bestak M
Drugs R D; 2003; 4(2):91-101. PubMed ID: 12718563
[TBL] [Abstract][Full Text] [Related]
11. The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma.
Burzynski SR; Janicki TJ; Burzynski GS; Marszalek A
Childs Nerv Syst; 2014 Dec; 30(12):2051-61. PubMed ID: 24718705
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme.
Burzynski SR; Lewy RI; Weaver R; Janicki T; Jurida G; Khan M; Larisma CB; Paszkowiak J; Szymkowski B
Integr Cancer Ther; 2004 Sep; 3(3):257-61. PubMed ID: 15312271
[TBL] [Abstract][Full Text] [Related]
13. Comment to the paper: The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma : Stanislaw R. Burzynski, Tomasz J. Janicki, Gregory S. Burzynski, Ania Marszalek.
Blaskiewicz R
Childs Nerv Syst; 2014 Dec; 30(12):2067-8. PubMed ID: 25146834
[No Abstract] [Full Text] [Related]
14. Comment to the paper "The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brain stem glioma" by Burzynski et al.
Wong TT
Childs Nerv Syst; 2014 Dec; 30(12):2069-70. PubMed ID: 25142686
[No Abstract] [Full Text] [Related]
15. Quick response of advanced cancer to chemoradiation therapy with antineoplastons.
Tsuda H; Sata M; Kumabe T; Hara H; Eriguchi N; Sugita Y; Nagamatsu H
Oncol Rep; 1998; 5(3):597-600. PubMed ID: 9538158
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma.
Tsuda H; Iemura A; Sata M; Uchida M; Yamana K; Hara H
Kurume Med J; 1996; 43(2):137-47. PubMed ID: 8755117
[TBL] [Abstract][Full Text] [Related]
17. Managing social conflict in complementary and alternative medicine research: the case of antineoplastons.
Hammer MR; Jonas WB
Integr Cancer Ther; 2004 Mar; 3(1):59-65. PubMed ID: 15035877
[TBL] [Abstract][Full Text] [Related]
18. Potential of antineoplastons in diseases of old age.
Burzynski SR
Drugs Aging; 1995 Sep; 7(3):157-67. PubMed ID: 8535046
[No Abstract] [Full Text] [Related]
19. Commentary on: "The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma." By Burzynski et al.
Perilongo G
Childs Nerv Syst; 2014 Dec; 30(12):2071-2. PubMed ID: 25330863
[TBL] [Abstract][Full Text] [Related]
20. Stanislaw R. Burzynski, MD, PhD: novel cancer research and the fight to prove its worth.
Burzynski SR
Altern Ther Health Med; 2012; 18(3):54-61. PubMed ID: 22875562
[No Abstract] [Full Text] [Related]
[Next] [New Search]
